2. Academic Validation
  3. Synthesis and anti-Helicobacter pylori activity of FR182024, a new cephem derivative

Synthesis and anti-Helicobacter pylori activity of FR182024, a new cephem derivative

  • Bioorg Med Chem Lett. 1999 Nov 1;9(21):3123-6. doi: 10.1016/s0960-894x(99)00549-1.
Y Yoshida 1,  K Matsuda,  H Sasaki,  Y Matsumoto,  S Matsumoto,  H Takasugi
Affiliations

Affiliation

  • 1 Medicinal Chemistry Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan.
PMID: 10560737 DOI: 10.1016/s0960-894x(99)00549-1
Abstract

The synthesis and anti-Helicobacter pylori activity of a novel cephem derivative FR182024 (1) are described. FR182024 having a (5-methyl-1,3,4-thiadiazol-2-yl)-thio moiety at the 3-position and a phenylacetamido at the 7-position was found to have extremely potent in vitro anti-H.pylori activity, superior therapeutic efficacy to AMPC and CAM, and low potential for causing diarrhea.

Figures
Products